Prof Simon Lo

USA

Prof Simon Lo

USA

Biography

Prof Simon Lo

Director, GI Endoscopy
Director, Pancreatic and Biliary Diseases Program
Cedars-Sinai Medical Center
Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA, USA


Education/Training

Institution and Location Degree Completion Date
MM/YYYY
Field of Study
Queens College, City University of New York, Flushing, NY B.A. 06/1976 N/A
George Washington University School of Medicine, Washington, DC N/A 06/1979 Internal Medicine
New York School of Medicine, New York, NY M.D. 06/1982 Internal Medicine
UCLA-Wadsworth VA Medical Center, Los Angeles, CA Internship & Residency 06/1985 Internal Medicine
UCLA-Integrated GI Training Program, Los Angeles, CA Fellowship 06/1987 Gastroenterology
Academisch Medisch Centrum, University of Amsterdam, Amsterdam, Netherlands Training 01/1990 Biliary Endoscopy

Personal Statement

My area of expertise is in pancreatobiliary disease and endoscopic interventions for these disorders. I am both the Director of GI Endoscopy and Director of Pancreatic and Biliary Diseases at Cedars-Sinai Medical Center; as such, I run a very large clinical program that cares for patients with the full range of pancreatobiliary disease, from Southern California and beyond. We have also built a very active clinical research program; with Dr. Stephen Pandol and Dr. Elham Afghani heading our basic science and translational pancreatobiliary research programs, these activities will continue to expand. I have been an investigator in a number of clinical studies examining pancreatobiliary disease progression, treatment and management of pancreatobiliary disease, and advanced endoscopic interventions.  Therefore, our group is structured to deliver high quality patient care and conduct research simultaneously. As a clinician, investigator, and teacher in pancreatic diseases for most of my professional career, I find the proposed work to be a potentially and critically important project in our field. I am motivated to carry out the objectives of the proposed research at the Cedars-Sinai Medical Center site.

Our group at Cedars-Sinai Medical Center sees over 1,000 new patients annually for evaluation and management of benign and malignant pancreatic disorders.  This, along with patients that are directly referred for endoscopic assessment of known or suspected pancreatic findings, provides us with roughly 1,200 patients for pancreatic endoscopic ultrasound (EUS) every year.  My role in this study is to provide the large volume of patients needed to explore and identify the Type 3c diabetes mechanism in the continuum of pancreatitis to pancreatic cancer. This center research aim is of great interest to me and I will devote the highest priority to it.